by Five Rivers Rx | Jan 4, 2019 | Industry News, Regulations
The first-time inspection of a wholesale drug distributor for DSCSA requirements is a warning to industry: be prepared for a knock on the door by the FDA. Why It’s Important For the very first time, the US Food and Drug Administration (FDA) performed an inspection and...
by Five Rivers Rx | Oct 31, 2018 | Industry News, Regulations
Continued political and public pressure has pushed sweeping changes to how the industry will transact Controlled Substance business. Agenda for DOJ/DEA Rulemaking 1117-AB47: Suspicious Orders From the DEA’s Proposed Rule: “The Drug Enforcement Administration is...
by Five Rivers Rx | Oct 9, 2018 | Regulations
Background In a letter dated May 23, 2018, AmerisourceBergen threatened to stop supply to Bernie’s Pharmacy because of “an elevated percentage of opioid purchasing…specifically, it was noted that in recent months between 25-50% of all pharmacy purchases of Rx products...
by Five Rivers Rx | Oct 2, 2018 | Industry News, Regulations
Telehealth technology presents a unique opportunity to revolutionize multiple aspects of healthcare. 2018 has been a breakout year for telehealth – the majority of states now allow the practice of telepharmacy and healthcare practitioners are becoming more receptive...
by Five Rivers Rx | Sep 19, 2018 | Regulations
The DEA hosted a conference in San Antonio, TX that addressed multiple aspects of how those that manufacture, purchase, and/or sell controlled substances are regulated. Topic 1: Opioid Epidemic Will Glaspy – Special Agent in Charge of the Houston DEA office –...
by Five Rivers Rx | Aug 28, 2018 | Regulations
Key Reductions, 2019 versus 2018 per HDA: ANPP 88% Codeine (for conversion) 90% Dihydrocodeine 90% Dihydromorphine* 74% Fentanyl 88% Hydrocodone (for conversion) 4% Hydrocodone (for sale) 89% Hydromorphone 90% Meperidine 58% Morphine (for sale) 93% Opium (tincture)...
